Literature DB >> 21102570

Differential expression of toll-like receptors in patients with irritable bowel syndrome.

Elizabeth K Brint1, John MacSharry, Aine Fanning, Fergus Shanahan, Eamonn M M Quigley.   

Abstract

OBJECTIVES: The pathogenesis of irritable bowel syndrome (IBS) is poorly understood. One contributory factor may be low-grade mucosal inflammation, perhaps initiated by the microbiota. Toll-like receptors (TLRs) are a family of pathogen-recognition receptors of the innate immune system. The aim of this study was to evaluate the potential involvement of TLRs in IBS to further understand the involvement of the innate immune system in this complex disorder.
METHODS: The expression of TLRs was investigated in colonic biopsy samples obtained from 26 IBS patients and compared with 19 healthy controls. Protein expression of TLR4, TLR7, and TLR8 was confirmed by immunofluorescence and alterations in the TLR4 protein were confirmed by western blot.
RESULTS: Quantitative reverse transcriptase-PCR showed increased levels of TLR4 (P≤0.001) and TLR5 (P=0.0013) and decreased levels of TLR7 (P≤0.001) and TLR8 (P=0.0019) in IBS patients.
CONCLUSIONS: Our results support the presence of an immune engagement between the microbiota and the host in IBS; an interaction that involves innate immunity and could generate a low-grade inflammatory response. These findings could also offer an additional biomarker of the disease or a disease subset.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102570     DOI: 10.1038/ajg.2010.438

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  87 in total

1.  Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling.

Authors:  Mallappa Anitha; Matam Vijay-Kumar; Shanthi V Sitaraman; Andrew T Gewirtz; Shanthi Srinivasan
Journal:  Gastroenterology       Date:  2012-06-23       Impact factor: 22.682

2.  Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.

Authors:  Jinjoo Kim; Kumsun Cho; Joo Sung Kim; Hyun Chae Jung; Bumsik Kim; Myeong Soo Park; Geun Eog Ji; Joo-Youn Cho; Kyoung Sup Hong
Journal:  Food Sci Biotechnol       Date:  2019-12-23       Impact factor: 2.391

Review 3.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 4.  The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis.

Authors:  N D Turner; L E Ritchie; R S Bresalier; R S Chapkin
Journal:  Curr Gastroenterol Rep       Date:  2013-09

Review 5.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

6.  RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study.

Authors:  Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-24       Impact factor: 4.052

Review 7.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 8.  Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?

Authors:  S E Kim; L Chang
Journal:  Neurogastroenterol Motil       Date:  2012-08-02       Impact factor: 3.598

Review 9.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

Review 10.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.